MedTrace Logo

Creon After Pancreatic Surgery

NCT00535756 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2011-08-18

No results posted yet for this study

Summary

This study will provide efficacy data for Creon 25000 MMS in PS patients as well as long-term safety data. During the long-term treatment with Creon 25000 nutritional parameters will be assessed and correlated with CFA

Conditions

  • Pancreatic Insufficiency

Interventions

DRUG

Creon

3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Data Map GmbH

    collaborator UNKNOWN

  • Abbott Products

    lead INDUSTRY

Principal Investigators

  • Guenter Krause, MD · Abbott Products

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Bulgaria
  • Germany
  • Hungary
  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00535756 on ClinicalTrials.gov